Protecting the Ischaemic and Reperfused Myocardium in Acute Myocardial Infarction: Distant Dream or Near Reality?

Overview

Journal Heart

Date 2000 Mar 18

PMID 10722532

Citations 32

Authors

D M Yellon

G F Baxter

Affiliations

Soon will be listed here.

Citing Articles

Nicotinamide ribose ameliorates myocardial ischemia/reperfusion injury by regulating autophagy and regulating oxidative stress.

Yuan C, Yang H, Lan W, Yang J, Tang Y Exp Ther Med. 2024; 27(5):187.

PMID: 38533432 PMC: 10964731. DOI: 10.3892/etm.2024.12475.

has renoprotective potentials in ischemia reperfusion injury in normal and diabetic rats.

Bhavsar V, Patel A, Vaghasiya J, Padhiyar S, Patel T Indian J Pharmacol. 2024; 55(6):367-375.

PMID: 38174533 PMC: 10821690. DOI: 10.4103/ijp.ijp_272_23.

Possible effects of melatonin on reperfusion injury following coronary artery bypass graft surgery.

Hajhossein-Talasaz A, Dianatkhah M, Ghaeli P, Salehiomran A, Dianatkhah M ARYA Atheroscler. 2023; 18(2):1-7.

PMID: 36819839 PMC: 9931614. DOI: 10.48305/arya.v18i0.2208.

A four-compound remedy AGILe protected H9c2 cardiomyocytes against oxygen glucose deprivation targeting the TNF-α/NF-κB pathway: Implications for the therapy of myocardial infarction.

Zhang X, Chen Q, Zhao J, Zhao W, Fan N, Wang Y Front Pharmacol. 2023; 14:1050970.

PMID: 36713834 PMC: 9880036. DOI: 10.3389/fphar.2023.1050970.

Puerarin: A protective drug against ischemia-reperfusion injury.

Gao M, Zhang Z, Lai K, Deng Y, Zhao C, Lu Z Front Pharmacol. 2022; 13:927611.

PMID: 36091830 PMC: 9449408. DOI: 10.3389/fphar.2022.927611.

References

Schultz J, Hsu A, Gross G . Ischemic preconditioning and morphine-induced cardioprotection involve the delta (delta)-opioid receptor in the intact rat heart. J Mol Cell Cardiol. 1997; 29(8):2187-95. DOI: 10.1006/jmcc.1997.0454. View

Patel D, Purcell H, Fox K . Cardioprotection by opening of the K(ATP) channel in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. CESAR 2 investigation. Clinical European studies in angina and.... Eur Heart J. 1999; 20(1):51-7. DOI: 10.1053/euhj.1998.1354. View

GARLID K, Paucek P, Yarov-Yarovoy V, Murray H, Darbenzio R, DAlonzo A . Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+ channels. Possible mechanism of cardioprotection. Circ Res. 1997; 81(6):1072-82. DOI: 10.1161/01.res.81.6.1072. View

Carr C, Hill R, MASAMUNE H, Kennedy S, Knight D, Tracey W . Evidence for a role for both the adenosine A1 and A3 receptors in protection of isolated human atrial muscle against simulated ischaemia. Cardiovasc Res. 1998; 36(1):52-9. DOI: 10.1016/s0008-6363(97)00160-0. View

Heusch G, Rose J, Ehring T . Cardioprotection by ACE inhibitors in myocardial ischaemia/reperfusion. The importance of bradykinin. Drugs. 1997; 54 Suppl 5:31-41. DOI: 10.2165/00003495-199700545-00006. View

Imagawa J, Baxter G, Yellon D . Myocardial protection afforded by nicorandil and ischaemic preconditioning in a rabbit infarct model in vivo. J Cardiovasc Pharmacol. 1998; 31(1):74-9. DOI: 10.1097/00005344-199801000-00011. View

Yaoita H, Ogawa K, Maehara K, Maruyama Y . Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor. Circulation. 1998; 97(3):276-81. DOI: 10.1161/01.cir.97.3.276. View

Frolich O, Karmazyn M . The Na-H exchanger revisited: an update on Na-H exchange regulation and the role of the exchanger in hypertension and cardiac function in health and disease. Cardiovasc Res. 1998; 36(2):138-48. DOI: 10.1016/s0008-6363(97)00200-9. View

Endres M, Namura S, Waeber C, Zhang L, Gomez-Isla T, Hyman B . Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family. J Cereb Blood Flow Metab. 1998; 18(3):238-47. DOI: 10.1097/00004647-199803000-00002. View

10.

Hsu A, Nagase H, Gross G . TAN-67, a delta 1-opioid receptor agonist, reduces infarct size via activation of Gi/o proteins and KATP channels. Am J Physiol. 1998; 274(3):H909-14. DOI: 10.1152/ajpheart.1998.274.3.H909. View

11.

Yellon D, Baxter G, Garcia-Dorado D, Heusch G, Sumeray M . Ischaemic preconditioning: present position and future directions. Cardiovasc Res. 1998; 37(1):21-33. DOI: 10.1016/s0008-6363(97)00214-9. View

12.

Mahaffey K, Puma J, Barbagelata N, DiCarli M, Leesar M, Browne K . Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol. 1999; 34(6):1711-20. DOI: 10.1016/s0735-1097(99)00418-0. View

13.

Braunwald E, Kloner R . Myocardial reperfusion: a double-edged sword?. J Clin Invest. 1985; 76(5):1713-9. PMC: 424191. DOI: 10.1172/JCI112160. View

14.

Opie L . Reperfusion injury and its pharmacologic modification. Circulation. 1989; 80(4):1049-62. DOI: 10.1161/01.cir.80.4.1049. View

15.

Liu G, Thornton J, Van Winkle D, Stanley A, Olsson R, Downey J . Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation. 1991; 84(1):350-6. DOI: 10.1161/01.cir.84.1.350. View

16.

Yellon D, Downey J . Current research views on myocardial reperfusion and reperfusion injury. Cardioscience. 1990; 1(2):89-98. View

17.

Woods K, Fletcher S, Roffe C, Haider Y . Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet. 1992; 339(8809):1553-8. DOI: 10.1016/0140-6736(92)91828-v. View

18.

Anderson H, Willerson J . Thrombolysis in acute myocardial infarction. N Engl J Med. 1993; 329(10):703-9. DOI: 10.1056/NEJM199309023291006. View

19.

Parratt J . Protection of the heart by ischaemic preconditioning: mechanisms and possibilities for pharmacological exploitation. Trends Pharmacol Sci. 1994; 15(1):19-25. DOI: 10.1016/0165-6147(94)90129-5. View

20.

Wall T, Sheehy R, Hartman J . Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther. 1994; 270(2):681-9. View